文献速递垂体与肾上腺疾病性腺与生殖内分泌

Crinecerfont降低21-羟化酶缺陷症成人患者的激素标志物

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项开放标签2期研究评估了选择性CRF1R拮抗剂crinecerfont在21OHD成人患者中的安全性、耐受性和疗效。18名患者接受4种口服方案之一治疗14天,结果显示100mg每日两次方案使ACTH、17OHP和雄烯二酮中位降幅均超过60%,女性睾酮下降≥50%者占73%。结论认为crinecerfont可降低ACTH并实现有临床意义的雄激素前体下降。

要点

  • crinecerfont 100mg每日两次治疗14天使ACTH、17OHP和雄烯二酮中位降幅均超过60%。
  • 女性患者中73%(8/11)睾酮水平下降≥50%。
  • 男性患者雄烯二酮/睾酮比值中位下降26%至65%。

核心结论

  • crinecerfont治疗14天可降低21OHD成人患者的ACTH,并使升高的17OHP、雄烯二酮、女性睾酮或男性雄烯二酮/睾酮比值出现有临床意义的下降。

研究设计与样本

  • 开放标签、2期、序贯队列设计研究(NCT03525886),在美国6个中心开展。
  • 纳入18名18至50岁21OHD男女患者(11名女性,7名男性),平均年龄31岁,94%为白人。
  • 4种crinecerfont口服方案各连续给药14天:50mg或100mg每日一次睡前、100mg每日一次晚间、100mg每日两次;参与者可入组多个队列。

主要发现

  • crinecerfont 100mg每日两次组ACTH中位降幅66%、17OHP降幅64%、雄烯二酮降幅64%。
  • 女性参与者中73%(8/11)睾酮水平下降≥50%。
  • 男性参与者雄烯二酮/睾酮比值中位下降26%至65%。

临床怎么用

  • crinecerfont可作为降低21OHD患者ACTH及肾上腺雄激素前体的潜在非糖皮质激素治疗选择。
  • 仍需长期研究评估crinecerfont对类固醇生成紊乱临床终点及糖皮质激素暴露的影响。

局限性

  • 开放标签设计,样本量小(18例),94%为白人,治疗仅14天。
  • 参与者可入组多个队列,可能影响组间比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess androgen production. Corticotropin-releasing factor type 1 receptor (CRF1R) antagonism may decrease adrenal androgen production. OBJECTIVE: This work aimed to evaluate the safety, tolerability, and efficacy of crinecerfont (NBI-74788), a selective CRF1R antagonist, in 21OHD. METHODS: This open-label, phase 2 study, with sequential cohort design (NCT03525886), took place in 6 centers in the United States. Participants included men and women, aged 18 to 50 years, with 21OHD. Interventions included 4 crinecerfont regimens, each administered orally for 14 consecutive days: 50 or 100 mg once daily at bedtime (cohorts 1 and 2, respectively); 100 mg once daily in the evening (cohort 3); and 100 mg twice daily (cohort 4). Participants could enroll in more than 1 cohort. Main outcomes included changes from baseline to day 14 in adrenocorticotropin (ACTH), 17-hydroxyprogesterone (17OHP), androstenedione, and testosterone. RESULTS: Eighteen participants (11 women, 7 men) were enrolled: cohort 1 (n = 8), cohort 2 (n = 7), cohort 3 (n = 8), cohort 4 (n = 8). Mean age was 31 years; 94% were White. Median percent reductions were more than 60% for ACTH (-66%), 17OHP (-64%), and androstenedione (-64%) with crinecerfont 100 mg twice a day. In female participants, 73% (8/11) had a 50% or greater reduction in testosterone levels; male participants had median 26% to 65% decreases in androstenedione/testosterone ratios. CONCLUSION: Crinecerfont treatment for 14 days lowered ACTH and afforded clinically meaningful reductions of elevated 17OHP, androstenedione, testosterone (women), or androstenedione/testosterone ratio (men) in adults with 21OHD. Longer-term studies are required to evaluate the effects of crinecerfont on clinical end points of disordered steroidogenesis and glucocorticoid exposure in patients with 21OHD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Auchus RJ, Sarafoglou K, Fechner PY, et al. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2022. PMID: 34653252. doi:10.1210/clinem/dgab749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。